Recent Blog Posts

View Post: Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With ...
18 Nov 2009 by Sandi Pniauskas  
2009] - PubMed result CONCLUSION: The regimen of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab is feasible, safe, and worthy of future study in advanced ovarian cancer. ovarian+cancer. Technorati Blog Finder ...
View Blog: OVARIAN CANCER and US - http://ovariancancerandus.blogspot.com/

---

View Post: The Whisper Network :: An Ovarian Cancer Community Blog » Blog ...
4 hours ago by Not Dying Today  
After another “debulking” surgery—that's where they remove as much cancer tissue as they possibly and safely can– I recuperated for about 10 days and then chemotherapy yet again. This time Carboplatin and Gemcitabine. ...
View Blog: The Whisper Network :: An Ovarian Cancer... - http://ovationsforthecure.org/whispernetwork/

---

View Post: SIGNS OF OVARIAN CANCER
24 Nov 2009
Both types of cancer are diagnosed in the same way, with the 'tumor marker' CA-125 BLOOD TEST, and they are treated in the same way - surgery to remove the primary tumor and then chemotherapy with Taxol and Carboplatin. ...
View Blog: Diary of ramnath rajaram - http://ramajayam.rediffiland.com/

---

View Post: Treating Mesothelioma Chemotherapy - Carboplatin
20 Nov 2009 by Jenny Lee  
Used carboplatin, a drug to combat the asbestos cancer mesothelioma, typically has more minor side effects than most chemotherapy treatments. However, it is also generally less effective, and must be administered in higher doses to suit ...
View Blog: Cancer Asbestos - http://cancer-asbestos-1.blogspot.com/

---

View Post: Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor ...
17 Nov 2009
Upregulation of PI3K signaling is associated with resistance to paclitaxel and carboplatin. Jennifer Wheler, MD from the University of Texas M. D. Anderson Cancer Center, Houston, TX, and an investigator on the phase 1 trial, ...
View Blog: Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html

---